Myeloid cells coordinately induce glioma cell-intrinsic and cell-extrinsic pathways for chemoresistance via GP130 signaling

Graphical abstract

Highlights
- Interaction of myeloid and tumor (GBM) cells induces humanin expression
- GBMs segregate inter-individually into humanin-sensitive or humanin-insensitive tumors
- In sensitive GBMs, humanin induces cell-autonomous and systemic chemoresistance
- Humanin-mediated therapy resistance can be addressed with clinically approved drugs

Authors
Jiying Cheng, Min Li, Edyta Motta, ..., Charlotte Flüh, Roland E. Kälin, Rainer Glass

Correspondence
rainer.glass@med.uni-muenchen.de

In brief
Cheng et al. show that glioblastoma (GBM) and myeloid cell interaction initiates paracrine signaling via the peptide humanin. Humanin activates GP130 receptors on vascular and GBM cells resulting in blood-tumor barrier formation and DNA damage response (DDR). This represents a bifurcated resistance pathway for chemotherapy. Therapeutic efficacy is restored by GP130 blockade.
Myeloid cells coordinately induce glioma cell-intrinsic and cell-extrinsic pathways for chemoresistance via GP130 signaling

Jiying Cheng,1,2,13 Min Li,1,13 Edyta Motta,3 Deivi Barci,1 Wangyang Song,1 Ding Zhou,1 Gen Li,1 Sihan Zhu,1 Anru Yang,1 Brian D. Vaillant,4 Axel Imhof,5 Ignasi Forneré,6 Sabine Spiegl-Kreinecker,6,7 Nu Zhang,2 Hiroshi Katayama,8 Krishna P.L. Bhat,9 Charlotte Flüh,10 Roland E. Kälin,1,6,13 and Rainer Glass 1,11,12,13,14,*

1Neurosurgical Research, University Hospital, LMU Munich, Munich, Germany
2Department of Neurosurgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, P.R. China
3Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin-Buch, Germany
4Department of Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA
5Protein Analysis Unit, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-University (LMU) Munich, Martinsried, Germany
6Department of Neurosurgery, Medical Faculty, Johannes Kepler University Linz, Linz, Austria
7Clinical Research Institute for Neurosciences, Johannes Kepler University Linz, Linz, Austria
8Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
9Department of Cancer Biology, Mayo Clinic, Scottsdale, AZ, USA
10Department of Neurosurgery, University Medical Center Göttingen, Göttingen, Germany
11German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and University Hospital Munich, Munich, Germany
12Institute of Surgical Research at the Walter Brendel Centre of Experimental Medicine, University Hospital, LMU Munich, Munich, Germany
13These authors contributed equally
14Lead contact
*Correspondence: rainer.glass@med.uni-muenchen.de
https://doi.org/10.1016/j.xcrm.2024.101658

SUMMARY

The DNA damage response (DDR) and the blood-tumor barrier (BTB) restrict chemotherapeutic success for primary brain tumors like glioblastomas (GBMs). Coherently, GBMs almost invariably relapse with fatal outcomes. Here, we show that the interaction of GBM and myeloid cells simultaneously induces chemoresistance on the genetic and vascular levels by activating GP130 receptor signaling, which can be addressed therapeutically. We provide data from transcriptomic and immunohistochemical screens with human brain material and pharmacological experiments with a humanized organotypic GBM model, proteomics, transcriptomics, and cell-based assays and report that nanomolar concentrations of the signaling peptide humanin promote temozolomide (TMZ) resistance through DDR activation. GBM mouse models recapitulating intratumoral humanin release show accelerated BTB formation. GP130 blockade attenuates both DDR activity and BTB formation, resulting in improved preclinical chemotherapeutic efficacy. Altogether, we describe an overarching mechanism for TMZ resistance and outline a translatable strategy with predictive markers to improve chemotherapy for GBMs.

INTRODUCTION

Glioblastomas (GBMs) are the most frequent malignant brain tumors among adults.1 Current clinical care for GBMs is largely palliative, and the poor response of GBMs to chemotherapy is a major barrier for successful therapy.1,2 One key component promoting temozolomide (TMZ, the chemotherapeutic standard of care) resistance is the DNA damage response (DDR) pathway in tumor cells.3 The repair of TMZ-induced DNA single-strand breaks is controlled by the ataxia telangiectasia and Rad3-related (ATR) kinase,3 which is recruited to stalled or collapsed replication forks together with the 9-1-1 DNA clamp complex.4,5 These molecules cooperatively enable a time window for DNA repair and promote recovery from a DNA replication arrest.4,5

Therapy resistance of GBMs is not only regulated through cell-intrinsic pathways but also evoked by the tumor microenvironment.2,6 Myeloid cells (GAMs; comprising both bone-marrow-derived macrophages and microglia) and vascular cells are among the most abundant microenvironmental cell populations in GBMs and exert tumor-supporting effects.6–8 The extensive vascular network in GBMs enables rapid expansion of the tumor mass.7,9 At the same time, the GBM vasculature insufficiently supplies blood-borne therapeutics into GBMs, since intratumoral vessels maintain a residual,
Myeloid and GBM cell interaction induces humanin expression

Next, we inspected humanin expression levels in cultivated mouse brain slices that were depleted from endogenous microglia (Figures S4A–S4D) and replenished with human induced pluripotent stem cell (hiPSC)-derived microglia (since humanin is a human-specific peptide). Some slice preparations also contained human stem-like GBM cells alone (hGBMs; Table S3) or hGBMs together with hiPSC microglia (schematic in Figure 2A). Notably, expression levels of humanin were augmented when hiPSC microglia and GBM cells were coexistent (Figures 2A and S4E). Next, we determined if forced expression of humanin can have a pathological impact. Furthermore, we considered that humanin can modulate cell viability through intracellular or extracellular pathways and generated hGBMs stably expressing wild-type humanin peptide (HN-WT; mediating intra- and extracellular effects) and hGBMs expressing humanin mutants that cannot be secreted (HN-L9R; retaining intracellular biological activity) or have no function at all (HN-C8A; Figure 2B). Expansion of these genetically manipulated hGBMs was quantified in vitro (Figure 2B). At the experimental endpoint, HN-WT cells had grown to much higher cell numbers as compared to hGBMs expressing humanin mutants, while the intracellularly active HN-L9R promoted viability only very moderately (as compared to the inactive HN-C8A controls or wild-type hGBM cells). This pinpointed a strong tumor-promoting effect by secreted humanin, which was evaluated in an immunodepletion experiment (we abstained from experiments with MT-RNR2 knockdowns since this led to deteriorated cell viability; Figure S5). Here, we generated conditioned medium from HN-WT cells that was either immunodepleted with a humanin-specific antibody or left under control conditions (using non-immune IgG), and then hGBMs were cultured in the resulting media (see schematic in Figure 2C). When quantifying hGBM cell numbers, we observed that the HN-WT-induced protumorigenic effect (Figure 2B) was fully abrogated in hGBM cells exposed to humanin-depleted media but was preserved in controls (Figure 2C). Altogether, this series of experiments indicated that GAM and GBM cell interaction promotes humanin expression and that humanin release supports GBM growth.

RESULTS

Humanin is abundantly expressed in GBMs

We purified GAMs from GBM biopsies or microglia from tumor-free human brains (Table S1) by flow cytometry according to established protocols (Figures S1A–S1D). In addition, one part of each sample was excised to determine GBM subtypes (Table S1). Gene ontology analysis of differentially expressed genes between GAMs and GBMs induces TMZ resistance in tumor cells and simultaneously promotes BTB formation. Hence, GAMs provide GBMs with a dual protection from chemotherapy; individual GBM cells gain improved ability for DNA repair, and intratumoral delivery of TMZ is attenuated. Remarkably, both mechanisms rely on a single signaling cue and can be synchronously inhibited by blunting GP130 receptor activity. Overall, we report a central, pathologically coordinating function of GAMs and a translatable strategy to augment the standard of care in GBMs.

Humanin induces chemoresistance in a subset of GBMs

We next addressed the question of whether humanin may have pathological potential in a wider set of GBMs. In a pharmacological assay, we exposed different hGBMs (Table S3) to different concentrations of synthetic humanin peptide (or the pharmacologically more potent mutant humanin-G [HNG]; in cell culture media free of standard growth factors, epidermal growth factor [EGF] and basic fibroblast growth factor [bFGF]). We observed that humanin-sensitive GBMs were growth stimulated specifically by nanomolar amounts of humanin (but not larger amounts), whereas insensitive GBMs required micromolar humanin or HNG concentrations (Figures S6A and S6B). The tumor-supportive effect was induced after repetitive humanin or HNG application but returned to control levels after humanin/HNG withdrawal (Figures S6C–S6F). Next, we investigated the pharmacological effects of humanin in more detail by exogenous application of humanin or HNG, which was partly combined with...
TMZ administration. Strikingly, we observed that humanin (with almost equal efficacy as HNG) rescued humanin-sensitive GBMs from the antitumorigenic effects of TMZ (Figures 2D–2F). Overall, we identified five GBM cultures undergoing chemoresistance in response to nanomolar humanin concentrations (here for brevity designated hGBM-1 to hGBM-5; Figure S7) and three GBM cultures requiring micromolar amounts of humanin for the induction of chemoresistance (hGBM-6 to hGBM-8; Figure S7). Flow cytometric analysis showed that TMZ strongly induced DNA fragmentation in hGBMs, which was blunted by coadministration of HN (20 nM) together with TMZ (100 μM; Figures 2G and 2H). Coherently, TMZ induced γ-H2AX foci and caspase-3 activity in GBM cells (Figure S8). Simultaneously, TMZ reduced labeling for the cell cycle marker Ki67 (Figure S8). Humanin application reverted these chemotherapeutic effects in GBM cultures (Figure S8). In summary,
Figure 2. Humanin promotes GBM chemoresistance

(A) hiPSC microglia or hGBMs were implanted (alone or in combination) into organ-cultured mouse brain slices; immunostained for humanin and staining was quantified.

(B) Humanin (HN) WT or mutant isoforms:

- HN-WT
- HN-L9R
- HNC8A

(hGBM)

(C) HN-WT conditioned medium

- HN-specific immuno-depletion vs. Ctrl. IgG

(hGBM)

(D) hGBM-1

- EGF + FGF
- HN (20 nM)
- HNG (20 nM)

(TMZ 100 μM)
(TMZ 300 μM)

(E) hGBM-2

- EGF + FGF
- HN (200 nM)
- HNG (200 nM)

(F) hGBM-3

- EGF + FGF
- HN (200 nM)
- HNG (200 nM)

(TMZ 100 μM)
(TMZ 300 μM)

(G) 7-AAD

- Ctrl.
- HN
- TMZ
- TMZ + HN

(H) Cells in SubG1 (%)

(TMZ)
(TMZ + HN)

(legend continued on next page)
GBMs segregate into tumors with high or low humanin sensitivity. The interplay of GAMs and GBMs promotes increased humanin expression, which can lead to increased TMZ resistance specifically in humanin-sensitive GBMs.

The protumorigenic effect of humanin requires GP130 and ERK activation

Our experiments showed that tumor-supportive effects were specifically mediated by extracellular humanin. The multimeric interleukin receptors (containing the glycoprotein GP130) and the formyl peptide receptors have previously been identified as plasma membrane receptors for humanin. Hence, we quantified the mRNA expression levels of IL6ST (GP130) in both humanin-sensitive and humanin-insensitive hGBMs by qPCR (Figures 3A and S9A–S9E). We detected robust IL6ST levels in humanin-sensitive hGBM-1, 2, and 3, but not in humanin-insensitive GBMs. Formyl peptide receptors were undetectable (Figures S8C–S8E) in agreement with results from GBM databases (Figure S9F). Next, we quantified tumor cell expansion of hGBM-1, 2, and 3 stimulated with humanin or HNG (using the most efficacious growth-stimulating peptide variant for each hGBM subset; see Figures 2D–2F) in the presence or absence of the GP130 antagonist sc144. We consistently observed that sc144 fully blocked humanin (or HNG)-stimulated hGBM growth (Figure 3B). In addition, we applied sc144 to hGBMs expressing HN-WT, HN-L9R, or HN-C8A. As expected, HN-WT tumor cells (without sc144) out-proliferated all other experimental groups, but application of sc144 fully blocked the growth-promoting effect of secreted humanin (Figure 3C); notably, HN-C8A or HN-L9R cultures remained unaffected by the antagonist (showing that sc144 has no toxic off-target effects). Of note, confirmatory results were obtained with an additional GP130 antagonist named bazedoxifene acetate (BZA; Figure S9G). Altogether, this demonstrated that humanin required GP130 to stimulate the growth of GBMs.

We also investigated the impact of GP130 signaling on GAM and GBM crosstalk in situ by applying our organotypic brain slice model (as introduced in Figure 2A). Coinjection of hiPSC microglia with hGBMs induced strong humanin expression specifically in the brain tumor mass, which was significantly reduced by the coadministration of sc144 (Figure 3D; see also Figure S4E). We explored if humanin expression in GBM cells was controlled via established GP130 agonists like ciliary neurotrophic factor, interleukin-6, leukemia inhibitory factor, oncostatin-M, or by humanin. Each cytokine was applied at an established bioactive concentration and humanin was applied at 200 nM; after 16 h, cells were analyzed for humanin expression and cell morphology (Figures S10 and S11). As compared to unstimulated controls (Figure S10A), humanin induced profound morphological changes in GBM cells (by inducing the formation of cell protrusions; Figure S10B) and upregulated the expression levels for humanin, which was not observed with any of the other cytokines (Figures S10C and S11). Conditioned medium from hiPSC microglia cell cultures also induced protrusion formation and humanin expression in GBM cells, which was both blocked by GP130 inhibition (Figures S11D and S11E). Stimulation of hiPSC microglia with recombinant humanin peptide or with conditioned medium from GBM cell cultures also induced protrusion formation (dependent on GP130), but did not lead to augmented humanin expression (Figures S12A and S12B). However, when we cocultivated hiPSC microglia with GBM cells, we consistently observed (GP130 dependent) induction of humanin expression in GBMs (Figure S4E) and also in hiPSC microglia (Figure S12C). In summary, this shows that the strong intratumoral humanin expression observed in many GBMs depends on GAM and GBM crosstalk via GP130 (Figure 3E). In brain tumor cells, humanin induces both biological reactions (chemoresistance and morphological alterations) as well as accelerated humanin expression. In microglia, the situation appears to be more complex; here humanin also induces morphological alterations, but humanin expression may also require physical contact with GBM cells.

Previous reports indicated that GP130 mediated therapy resistance through Stat3 activation. Surprisingly, western blotting experiments of hGBMs exposed to HNG (versus vehicle controls) showed induction of mitogen-activated protein kinase (ERK1/2) signaling, whereas STAT3 or AKT activity was not altered (Figure 4A). Performing this experiment on a different timescale gave similar results (Figure S13). Therefore, we explored if ERK signaling may drive humanin-induced chemoresistance and applied the ERK-selective antagonist raxoxertinib (GDC-0994) to hGBM-1, 2, and 3 cells treated with TMZ and humanin. We found that raxoxertinib fully and consistently abrogated humanin-induced chemoresistance (Figure 4B). To gain additional insight into the humanin-controlled signaling cues promoting TMZ resistance, we compared the transcriptional profile of humanin-sensitive (hGBM-1, 2, and 3) and humanin-insensitive hGBMs (hGBM-6, 7, and 8; Table S4) and noted that hGBM-1, 2, and 3 had elevated expression levels of genes relating to TMZ resistance and GP130 signaling (Figure S14A).
However, knockdown of a STAT3-activating component (Figure S14B and S14C) did not consistently blunt TMZ resistance in humanin-sensitive GBMs (Figure S14D). Altogether, our data support a central role for ERK (but not STAT3) signaling in humanin-induced chemoresistance.

We validated an immunohistochemical method detecting humanin-like peptides in mice32 (Figure 4C) and detected a basal level of humanin immunopositivity in the cerebellum but not in the forebrain (Figure 4D). Orthotopic implantation of Gl261 cells (a mouse glioma cell line; Figures 4E and S2E) did not lead to humanin expression, but injection of hGBM1 (overexpressing HN-WT) into the brain resulted in strong and homogeneous humanin immunopositivity throughout the entire GBM area (Figures 4F and S2C). We used this model to treat established, orthotopic HN-WT GBMs with TMZ and coapplied (intraperitoneally [i.p.]) the MEK inhibitor mirdametinib (blocking MEK-induced ERK1/2 activation)33 or vehicle (control). Mirdametinib, which is currently investigated in clinical trials for low-grade gliomas (NCT04923126), promoted survival throughout a chemotherapy schedule in our preclinical model (Figure 4G). Hence, our in vitro and in vivo experiments have consistently shown that ERK blockade is a therapeutically efficacious and fully translatable approach to blunt humanin-induced chemoresistance. Altogether, it broadens our view on the diverse pathological roles of the GP130 receptor subunit and indicates that stimulation of GP130 with humanin drives TMZ resistance through the ERK pathway (Figure 4H).

Humanin-induced chemoresistance is controlled by the HUS1, ATR pathway
To obtain further mechanistic insight how humanin promoted chemoresistance, we performed two consecutive RNA sequencing studies (Figures 5A and 5B) in humanin-sensitive GBMs. By filtering for the coherently expressed genes from...
Figure 4. GP130-mediated ERK signaling is required for humanin-induced chemoresistance
(A) hGBM1 cells were stimulated with HNG or left untreated (0 min) and analyzed by western blotting.
(B) Application of HN improved the viability of TMZ-treated hGBM-1, 2, or 3. Cotreatment with the ERK inhibitor ravoxertinib (RAV) consistently abrogated HN-induced chemoresistance.
(C) Humanin-like peptide is expressed in the mouse colon (positive control; immunostaining partly counterstained with hematoxylin/eosin; H + E), but not in the mouse forebrain (D) or mouse gliomas (GL261; E).
(F) Humanin was immunolabeled in orthotopic HN-WT GBMs (tumor is indicated by a dotted line; area pointed out by arrow is magnified).
both experiments (Table S5), we uncovered a molecular network with functional annotations in the ATR-controlled DNA damage pathway, neurodegeneration, and apoptosis (Figures S5B and S15A). From the list of genes within this network, we explored which factors have clinical relevance in GBMs (Figure S15B). This showed a negative prognostic property for the humanin-induced gene HUS1, which was particularly pronounced for the mesenchymal GBM subtype (Figure 5C). Knockdown of HUS1 in hGBMs strongly reduced cell viability (Figure S15C) in accordance with data from Cancer Dependency Maps (precluding further experiments using Hus1 knockdown vectors; Figure S15D). In agreement with our observation on a central role of ERK signaling in humanin-mediated therapy resistance, we found that humanin-induced Hus1 expression was blunted with the ERK inhibitor ravexertinib (Figures S15E and S15F). Coherent data were retrieved from a proteomics study comparing hGBM1 cells under control conditions or after stimulation with humanin (200 nM) for 15 min or 12 h (Figure S16). This showed that humanin did not trigger large changes in protein phosphorylation with humanin (200 nM) for 15 min or 12 h (Figure S16). This showed a negative prognostic property for the humanin-promoted GBM growth and chemoresistance (Figure 5H).

**ATR activity.** Collectively, our data show that HUS1 and ATR are responsible for humanin-promoted GBM growth and chemoresistance (Figure 5H).

### **GP130 inhibition blocks humanin-induced chemoresistance in vivo**

Further insight into humanin-induced therapy resistance was obtained with our *in vivo* model. Therefore, we orthotopically implanted HN-WT hGBMs (secreting the active form of humanin) or HN-C8A cells (inactive humanin mutant) and applied TMZ (or vehicle) according to established schedules. Mice were sacrificed at a fixed endpoint, and tumor size in each experimental group was quantified. The HN-C8A tumors responded well to TMZ treatment, but HN-WT cells were fully rescued from the therapeutic effects of TMZ even after extended application (14 days) of a high TMZ concentration (Figure 6A). Both the *in vivo* model (Figure 6A) and the organotypic brain slice model (Figures S17B–S17F) showed that humanin does not promote tumor growth of GBMs that are embedded in a cellular microenvironment (in contrast to an *in vitro* situation; Figures 2D–2F). The main pathological effect of humanin in *vivo* is the induction of TMZ resistance (Figure 6A), which was also detected in *vitro* (Figures 2D–2F).

To study the *in vivo* pathways for this apparent chemoresistance in more detail, we injected hGBM-1 cells into mouse brains, infused humanin or artificial cerebrospinal fluid (aCSF) into the tumor mass, and treated the animals with i.p. injections of BZA, which is BTB permeable, or vehicle (Figure 6B). Brains were harvested, and immunofluorescence for HUS1 (as a marker for humanin-promoted GP130 signaling and chemoresistance) was inspected. Intratumoral infusion of aCSF generated tumors with weakly detectable levels of HUS1, while immunofluorescence density for HUS1 was much stronger in humanin-infused GBMs, which was blocked by i.p. application of BZA (Figure 6B, for higher magnification micrographs, see Figure S18). Since BZA blunted the humanin-stimulated expression of HUS1, we investigated if BZA would therapeutically support TMZ treatment in humanin-expressing GBMs. One week after implanting HN-WT cells into mouse brains (and verifying GBM growth), we treated all mice with TMZ and one cohort was i.p. cotreated with BZA, whereas another received vehicle (as a control; schematic in Figure 6C). At the predetermined endpoint, tumor size was assessed, and we noted that HN-WT GBMs receiving cotreatment with TMZ and BZA were substantially smaller than HN-WT tumors receiving TMZ plus vehicle (Figure 6C). Consequently, our series of *in vivo* studies showed that humanin promotes TMZ resistance of GBMs and that BZA restores the chemotherapeutic properties of TMZ (consistently, BZA promoted TMZ-induced tumor cell death; Figure 6D).

The detailed histopathological inspection of our humanin-expressing GBMs *in vivo* models (HN-WT GBMs) also suggested an angiogenic role of humanin. After immunolabeling these

---

**Notes:**

1. (G) HN-WT GBMs (as in H) received TMZ together with systemic application (i.p.) of the MEK (ERK pathway) inhibitor mirdanetinib (10 mg/kg, i.p.; *n* = 10 mice) or vehicle (*n* = 8 mice) and overall survival was quantified.
2. (H) Schematic summary: extracellular humanin induces GP130-mediated chemoresistance in GBMs, which can be addressed therapeutically. The number of biological replicates is indicated (dots in graphs indicate data from individual experiments); all error bars are presented as mean ± SDM. Statistical significance is shown by one-way ANOVA in (B) or Mantel-Cox test (G): *p < 0.05, **p < 0.01, ***p < 0.001. Scales indicate 200 μm (C) or 1 mm (D–F).
Figure 5. Humanin-induced chemoresistance requires ATR signaling
(A) hGBM1 cells were stimulated with HN or vehicle (Ctrl.), underwent transcriptomics, and differentially expressed genes (DEGs) were analyzed by bioinformatics.

(legend continued on next page)
preclinical tumor models with vascular markers, we found that HN-WT GBMs showed accelerated vascularization and altered vessel morphology (Figure 6E). In accordance with the anti-angiogenic role of TMZ, chemotherapy blunted neoangiogenesis (Figure 6E). Strikingly, coapplication of BZA strongly supported the anti-angiogenic effects of TMZ application (Figure 6F) without accelerating GBM cell invasion (Figure S19A). Altogether, we observed a profound chemotherapy-supporting effect of BZA on both the level of GBM cytotoxicity and neoplastic angiogenesis.

**GP130 inhibition blocks blood-tumor barrier formation**

In HN-WT GBMs (versus HN-C8A controls), we noted a strong increase in platelet-derived growth factor-receptor-beta (PDGFRB) expressing vascular mural cells (pericytes), which was unaffected by TMZ application (Figure 7A). Furthermore, we observed that BZA-treated HN-WT GBMs did not exhibit increased pericyte coverage of tumor vessels (Figures 7B and 7C). Since the interaction of pericytes and endothelia may contribute to BTB formation and therapy resistance in GBMs,37 we inspected both cell types in a transcriptomics experiment. We inoculated GL261 cells into transgenic mice allowing the tracing of pericytes (see STAR Methods), infused humanin or vehicle (aCSF), and purified (by flow cytometry) endothelia or pericytes from GBMs (Figure 7D). Analysis of differentially expressed genes (Table S10) and gene set enrichment analysis (GSEA) revealed a proangiogenic effect of humanin on endothelia (Figure 7D; differentially expressed genes for pericytes are listed in Table S11). Since interaction of vascular cells is required for barrier formation,38 we inspected cell communication in humanin-infused versus control GBMs (with ICELLNET and the murine CellPhoneDB). This revealed a profound impact of humanin on pericyte to endothelial communication (and vice versa; Figures S19B and S19C). We concentrated on the ligand-receptor-pairs receiving the highest signifying scores in humanin (and not vehicle)-treated groups (Figure 7E), which revealed elevated bone morphogenetic protein (BMP) signaling (with established angiogenic traits46) from endothelia to pericytes. Notably, pericyte-derived factors were associated with IL6ST (GP130) receptor activation in endothelia, specifically in humanin-infused GBMs. A role for GP130 signaling endothelia-pericyte interaction was corroborated when quantifying the vascular mural cell coverage of GBM blood vessels in humanin-containing, TMZ-treated tumors (as compared to GBMs without BZA treatment; Figures 7F, S20A, and S20B). This indicated that systemic BZA application reduced vascular pericyte coverage in HN-WT GBMs and suggested that BZA treatment may interfere with BTB formation. We investigated this hypothesis by intravenous (i.v.) injection of a fluorescent vascular tracer (70 kDa) into the HN-WT GBM models in a chemotherapy paradigm with or without BZA application. Strikingly, we found that the tracer strongly and specifically accumulated in tumors of BZA-treated mice but not in control tumors (Figures 7G, S20C, and S20D). Altogether, this indicated that humanin promotes BTB formation, which is abrogated by BZA treatment. This finding opened the possibility that GP130 blockade in humanin-sensitive GBMs may exert a dual therapy-supporting role: GP130 inhibition promotes delivery of therapeutics by blunting the BTB and then suppresses chemoresistance of GBMs. To explore this scenario, we performed a survival study (using HN-WT GBMs plus TMZ treatments) and applied the specific GP130 inhibitor sc144 (or vehicle) via minipumps. Here, we did not apply BZA, as this substance (which is clinically used as an estrogen receptor antagonist41) had a side effect on body weight upon prolonged administration. We observed that sc144-mediated blockade of GP130 resulted in a strong TMZ therapy-supporting effect in humanin-secreting GBMs (Figure 7H). Hence, in humanin-sensitive GBMs, GP130 inhibitors have a strong, multi-modal chemotherapy-supporting effect (Figure 7I).

**DISCUSSION**

Resistance to TMZ is a major issue in clinical care for GBMs,2 and cell-autonomous mechanisms preventing TMZ efficacy have predictive capacity in neurooncology.1 Simultaneously, TMZ delivery into GBMs is locoregionally inefficient due to BTB formation.9 However, diagnostic markers and therapeutic measures tackling BTB induction still require entry into routine clinical practice for neurooncology.23 In the present study, we uncovered that GAMs promote chemoresistance both on the level of single tumor cells and on the level of systemic delivery of therapeutics. We identified high intratumoral levels of the peptide humanin as a risk factor for BTB development, showed that HUS1 is linked with humanin-mediated DNA repair, and uncovered GP130 inhibition as a treatment strategy to simultaneously suppress systemic and cell-autonomous resistance for TMZ.

MRI-based diagnostics for GBMs partly rely on an attenuated vascular barrier function in brain tumors.1,10 However, with the advent of different imaging modalities in neurooncology, it became clear that vascular barrier formation is subject to profound locoregional heterogeneity9 and that the BTB protects large parts of a given GBM from blood-borne therapeutics.9 Our data exhibit an unforeseen role of humanin in controlling...
Figure 6. Humanin-induced chemoresistance can be blocked therapeutically

(A) Tumor size of orthotopic HN-WT or HN-C8a tumors was compared in mice receiving TMZ or vehicle (in animals with established tumor growth, 5x per week for 2 weeks; pre-defined endpoint was at 3 weeks).

(legend continued on next page)
Brain tumor vascularization and BTB induction. We observed that humanin release in GBMs increases pericyte coverage in GBM vessels and blocks intratumoral accumulation of i.v. applied tracers. We demonstrate that humanin activates GP130 receptors in GBM cells and that GP130 inhibition blunts humanin-induced BTB induction. It is established that brain endothelia express GP130, but only few pharmacological pathways for BTB modulation were previously discovered and a role for GP130 in BTB maintenance was not explored. Our data suggest GP130 inhibition in humanin-sensitive tumors as a promising option to promote TMZ entry into neoplastic areas and simultaneously block GBM DNA repair. This is supported by our *in vivo* studies showing that blunting cell-intrinsic mechanisms for TMZ resistance with mirdametinib had a moderate chemotherapy-supporting effect, while application of the GP130 antagonist sc144 leveraged TMZ-based therapy without apparent adverse effects mediated by sc144. In this context, it is important to note that the BTB-penetrating GP130 blocker BZA can have unwanted effects, since BZA is an estrogen receptor antagonist, which reduced body weight in our preclinical models after prolonged application.

Currently, O6-methylguanine DNA methyltransferase (MGMT) methylation status serves as a stratifying marker for chemotherapy in GBMs. However, the MGMT status alone does not always represent a fully satisfactory marker for treatment decisions. The present study widens the repertoire of markers for TMZ application and shows that expression levels for humanin, HUS1, and GP130 are candidate predictive markers for TMZ treatment. We found that nanomolar concentrations of humanin are sufficient to induce GP130-mediated ER1/2 signaling and TMZ resistance via the ATR DDR pathway. Coherently, application of MEK/ERK inhibitors—and even more efficiently GP130 inhibitors—restored TMZ sensitivity. Hence, the development of BTB-penetrating GP130 antagonists is a promising route to augment TMZ treatment, and likely also more targeted therapies, in neurooncology.

The cytoprotective effects of humanin were discovered in neurodegenerative disease and have been confirmed in a larger number of studies. Treatment of tumor cells with chemotherapeutics may contribute to humanin release. However, this observation requires additional investigation since it was made with GBM cells corresponding to humanin-insensitive cells of the present study. We uncovered the pathological role of humanin after genetic screens in patient-derived GBMs, and our brain slice experiments showed that humanin is expressed upon interaction of GBM cells with GAMs. Subsequent *in vitro* assays indicated that secreted humanin initiates TMZ resistance at nanomolar concentrations of extracellular humanin. This was confirmed by an immunodepletion experiment. Transcriptomics, western blotting, and genetic manipulation indicated a molecular mechanism for humanin-induced chemoresistance. Under *in vitro* conditions, humanin exerted even a wider spectrum of tumor-supporting traits and also promoted GBM cell expansion. This was not observed in our orthotopic mouse models. We interpret that humanin-induced chemoresistance is a robust pathological effect prevailing even in the complex GBM microenvironment, while tumor parenchymal signals may blunt the growth-promoting impact of humanin (which is therefore restricted to an *in vitro* condition).

Clinical and preclinical research has shown that GAMs are legitimate targets for adjuvant treatment of GBMs. However, it also became clear that GAM-directed therapies require careful characterization of the tumor parenchyma and of GBM cells in order to stratify individuals for a specific treatment. This study complies with these stringent criteria and outlines a preclinical strategy to identify humanin-sensitive GBMs for which GP130 inhibitors have an overarching, synergistic effect to support TMZ efficacy. Hence, this provides a basis to improve the standard of care in a large group of patients with GBMs.

**Limitations of the study**

In our GBM mouse models, we have recapitulated humanin signaling by orthotopically implanting humanin-sensitive GBM cells and partly infused nanomolar amounts of humanin (or vehicle). In other experiments, we overexpressed functionally released humanin isoforms (as compared to experiments with an inactive isoform). This was necessary in order to substitute for humanin expression in GAMs, which is lacking in mouse myeloid cells. Our bioassays with humanin-sensitive hGBM1-HN-WT cells suggested that humanin release from genetically manipulated GBMs was biologically adequate: humanin-sensitive GBMs respond specifically to nanomolar (but not higher) concentrations of humanin and the HN-WT expression in hGBM1 cells stimulated cell growth (hence was stimulated by humanin). However, this model is limited by the fact that humanin release may not be representative of the complex GBM microenvironment, while tumor parenchymal signals may blunt the growth-promoting impact of humanin (which is therefore restricted to an *in vitro* condition).

Intravenous tracing, histopathology, and pharmacological experiments confirmed the multi-modal protumorigenic effects of humanin in GBMs and indicated a therapeutic solution. Altogether, this highlighted the pathological role of humanin signaling in neuropathology.

---

**B** Orthotopic hGBM1 was infused with HN (100 nM) or vehicle (artificial cerebrospinal fluid, aCSF) and i.p. injected with bazedoxifene-A (5 injections of BZA per week: 40 mg/kg; for 2 weeks) or vehicle; brains were labeled for HUS1; HUS1 expression was quantified.

**C** Mice with established, orthotopic HN-WT tumors received TMZ (50 mg/kg) and were cotreated with vehicle or BZA (as in B); after 3 weeks, tumor size was quantified (dashed line: average data from untreated WT GBMs).

**D** Mice with HN-WT GBMs received TMZ and were cotreated with vehicle or BZA (as in C); GBM samples were immunostained for active caspase-3 and immunolabeling was quantified (dashed line: average data from untreated WT GBMs).

**E** Intratumoral vascularization and vessel diameter were compared in HN-WT or HN-C8a tumors receiving TMZ.

**F** The HN-WT GBM mouse model was i.p. injected with TMZ and cotreated either with BZA or vehicle and the extent of intratumoral vascularization was compared. The number of biological replicates is indicated (dots in graphs indicate data from individual mice); all error bars are presented as mean ± SDM. Statistical significance is shown by one-way ANOVA (A, E), two-way ANOVA (B–D), or t test (F): *p* < 0.05, **p** < 0.01, ***p** < 0.001, ****p** < 0.0001; NS, not significant. Scale bars in (B, C) indicate 1 mm; scales in (D) represent 500 (overview) or 10 μm (magnified).
Figure 7. Humanin-mediated BTB formation is blunted by GP130 blockage increasing chemotherapeutic efficacy and survival

(A) Quantification of vascular mural coverage on tumor vessels in orthotopic HN-WT or HN-C8a GBMs with or without TMZ (indicated by blue bars).

(B and C) Vascular mural coverage of tumor vessels in TMZ-treated orthotopic HN-WT GBMs with or without BZA.

(D) Schematic showing the interaction between humanin and tumor vessels.

(E) Most contributing interactions (Pericyte_HN -> others)

(F) Vascular mural coverage of tumor vessels in TMZ-treated orthotopic HN-WT GBMs with or without BZA.

(G) Dextran extravasation (μm² x 1000) in orthotopic HN-WT GBMs with or without BZA.

(H) Survival probability of mice with or without SC144 treatment and TMZ.

(I) Schematic showing the role of humanin in GBM resistance and the potential therapeutic implications.

(legend continued on next page)
STAR+METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Mice
  - Human glioblastoma specimens
  - Cell culture
- **METHOD DETAILS**
  - Transcriptomics
  - Proteomics
  - q-RT-PCR
  - Genetic manipulation
  - Cell counting
  - Immunodepletion
  - Cell cycle analysis
  - Western blotting
  - Mouse brain slice culture
  - In vivo experiments
  - Intracerebral drug application
  - Single cell preparation and fluorescence-activated cell sorting of intracerebrally HN-treated tumor vasculature
  - Dextran leakage assay
  - Histology and immunostaining
  - Immunofluorescence staining
  - Immunofluorescence staining for human GBMs samples
  - Immunohistochemistry for mouse samples
  - Microscopy
  - Tumor volume quantification
  - Quantiﬁcation of tumor vasculature and pericyte coverage
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.xcrm.2024.101658.

ACKNOWLEDGMENTS

Funding by the Deutsche Forschungsgemeinschaft (DFG) in the Priority Program, “Local and Peripheral Drivers of Microglial Diversity and Function” (SPP 2395) is gratefully acknowledged by C.F. (FL 1123/4-1) and R.G. (GL 691/9-1) and funding by the Anni Hofmann Stiftung, “Wilhelm Sander-Stiftung” (SPP 2395) is gratefully acknowledged by C.F. (FL 1123/4-1) and R.G. (GL 691/8-1). R.G. and R.E.K. also acknowledge DFG grants GL 691/9-1 and R.E.K., and R.G. wrote the manuscript; and all authors discussed, revised, and approved of the manuscript.

REFERENCES


<references>

(D) Endothelial cells and pericytes were purified from a transgenic GBM mouse model (GL261, n = 11; infused with humanin, HN, or aCSF, control) and analyzed by transcriptomics; GSEA indicated enrichment for angiogenic traits in HN-stimulated endothelium (as compared to aCSF).

(E) Signaling pathways between endothelia and pericytes were analyzed from HN-infused versus control GBMs; in HN-infused GBMs, pericytes promote IL6ST (GP130) signaling in endothelia; in HN-infused GBMs, endothelia promote BMP signaling in pericytes.

(F) In HN-WT GBMs, receiving TMZ cotreatment with BZA reduced pericyte (PDGFRB+) coverage of tumor vessels (CD31+); as compared to cotreatment with vehicle.

(G) Intravenous application of 70 kDa dextran as a tracer for vessel tightness showed that BZA-treated gliomas had signiﬁcantly increased leakage (across CD31+ vessels) into the tumor parenchyma, as compared to vehicle-treated mice.

(H) In mice with orthotopic HN-WT GBMs, intracerebral infusion of sc144 (10 μM) during TMZ chemotherapy prolonged survival as compared to intracerebral infusion of vehicle (n = 12 per group).

(I) Schematic summary: the BTB and DDR protect humanin-sensitive GBMs from TMZ. GP130 inhibitors reduce BTB tightness and blunt chemoresistance. Scale bars indicate 200 μm in (A) and 20 μm in (G). The number of biological replicates is indicated (dots in graphs denote data from individual mice); all error bars are presented as mean ± SDM. Statistical signiﬁcance is shown by one-way ANOVA (A), t test (F, G), or by Mantel-Cox test (F): *p < 0.05, **p < 0.01, ***p < 0.001.
</references>


## STAR Methods

### Key Resources Table

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibodies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rat anti- CD31</td>
<td>Becton Dickinson</td>
<td>Cat#: 550274; RRID: AB_393571</td>
</tr>
<tr>
<td>Rabbit anti-Humanin</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#: PA1-41325; RRID: AB_1957735</td>
</tr>
<tr>
<td>Rabbit anti-Humanin</td>
<td>Biorbyt</td>
<td>Cat# orb157596</td>
</tr>
<tr>
<td>Goat anti- PDGFR-b</td>
<td>R&amp;D Systems</td>
<td>Cat#: AF1042; RRID: AB_2162633</td>
</tr>
<tr>
<td>Goat anti- Iba1</td>
<td>Abcam</td>
<td>Cat#: ab5076; RRID: AB_2224402</td>
</tr>
<tr>
<td>Mouse anti- IDH1-R132H</td>
<td>Dianova</td>
<td>Cat# DIA-H09, RRID:AB_2335716</td>
</tr>
<tr>
<td>Rabbit anti Laminin</td>
<td>Sigma</td>
<td>Cat# L9393, RRID:AB_477163</td>
</tr>
<tr>
<td>Mouse anti human-nuclei</td>
<td>Millipore</td>
<td>Cat# FCMAB306P, RRID:AB_10807437</td>
</tr>
<tr>
<td>Rabbit anti cleaved caspase3</td>
<td>Cell Signaling Technology</td>
<td>Cat# 9664; RRID:AB_2070042</td>
</tr>
<tr>
<td>Rabbit anti- HUS1</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# P5-109839, RRID:AB_2855250</td>
</tr>
<tr>
<td>Rabbit anti- Phospho-Histone H2A.X (Ser139)</td>
<td>Cell Signaling Technology</td>
<td>Cat# 9718, RRID:AB_2118009</td>
</tr>
<tr>
<td>Biotinylated Donkey anti- rabbit IgG</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 711-065-152RRID: AB_2340593</td>
</tr>
<tr>
<td>Alexa Fluor 488 Donkey anti-rabbit IgG</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 711-545-152; RRID: AB_2313584</td>
</tr>
<tr>
<td>Alexa Fluor 594 Donkey anti-rabbit IgG</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 711-585-152; RRID: AB_2340621</td>
</tr>
<tr>
<td>Alexa Fluor 647 Donkey anti-rabbit IgG</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 711-606-152; RRID: AB_2340625</td>
</tr>
<tr>
<td>Biotinylated Horse anti- goat IgG</td>
<td>Vector Laboratories</td>
<td>Cat# BA-9500; RRID:AB_2336123</td>
</tr>
<tr>
<td>Biotinylated Donkey anti- goat IgG</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 705-065-147 RRID: AB_2340397</td>
</tr>
<tr>
<td>Alexa Fluor 488 Donkey anti- goat IgG</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 705-545-147; RRID: AB_2336933</td>
</tr>
<tr>
<td>Alexa Fluor 647 Donkey anti- goat IgG</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 705-605-003; RRID: AB_2340436</td>
</tr>
<tr>
<td>Biotinylated Donkey anti- rat IgG</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 12-055-153; RRID: AB_2340643</td>
</tr>
<tr>
<td>Biotinylated goat anti- rat IgG</td>
<td>Vector Laboratories</td>
<td>Cat# BA-9400, RRID:AB_2336202</td>
</tr>
<tr>
<td>Cy 5 conjugated Donkey anti-rat IgG</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 712-175-150; RRID: AB_2340671</td>
</tr>
<tr>
<td>Alexa Fluor 594 Donkey anti- rat IgG</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 712-585-150; RRID: AB_2340688</td>
</tr>
<tr>
<td>Alexa Fluor 647 Donkey anti- rat IgG</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 712-585-150; RRID: AB_2340688</td>
</tr>
<tr>
<td>Cy 2 conjugated Donkey anti-rat IgG</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 712-175-150; RRID: AB_2340673</td>
</tr>
<tr>
<td>Biotinylated Donkey anti-chicken IgG</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 703-065-155; RRID: AB_2313596</td>
</tr>
<tr>
<td>FITC conjugated Donkey anti-chicken IgG</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 703-095-155; RRID: AB_2340356</td>
</tr>
<tr>
<td>Alexa Fluor 488 conj. Streptavidin</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 016-540-084; RRID: AB_2337249</td>
</tr>
<tr>
<td>Alexa Fluor 594-streptavidin conjugate</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 016-580-084; RRID: AB_2337250</td>
</tr>
<tr>
<td>Alexa Fluor 647-streptavidin conjugate</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 016-600-084; RRID: AB_2341101</td>
</tr>
<tr>
<td>Biotinylated Isolectin B4 (IB4)</td>
<td>Santa Cruz</td>
<td>Cat# sc-1205, RRID:AB_2155054</td>
</tr>
<tr>
<td>Rabbit anti- Akt</td>
<td>Cell Signaling Technology</td>
<td>Cat# 9272, RRID:AB_329827</td>
</tr>
<tr>
<td>Rabbit anti- phosho-AKT S473</td>
<td>Cell Signaling Technology</td>
<td>Cat# 4060, RRID:AB_2315049</td>
</tr>
<tr>
<td>Rabbit anti- ATR</td>
<td>Cell Signaling Technology</td>
<td>Cat# 2790, RRID:AB_2227860</td>
</tr>
<tr>
<td>Rabbit anti- phosho-ATR T1989</td>
<td>Cell Signaling Technology</td>
<td>Cat# 30632, RRID:AB_2798992</td>
</tr>
<tr>
<td>Rabbit anti- phosho-ERK1/2 T202/Y204</td>
<td>Cell Signaling Technology</td>
<td>Cat# 4370, RRID:AB_2315112</td>
</tr>
<tr>
<td>Rabbit anti- ERK1/2</td>
<td>Cell Signaling Technology</td>
<td>Cat# 9102 (also 9102L, 9102S), RRID:AB_330744</td>
</tr>
<tr>
<td>Rabbit anti- GAPDH</td>
<td>Cell Signaling Technology</td>
<td>Cat# 5174, RRID:AB_10622025</td>
</tr>
<tr>
<td>Rabbit anti- STAT3</td>
<td>Cell Signaling Technology</td>
<td>Cat# 4904, RRID:AB_331269</td>
</tr>
<tr>
<td>Rabbit anti- phosho-STAT3 Y705</td>
<td>Cell Signaling Technology</td>
<td>Cat# 9145, RRID:AB_2491009</td>
</tr>
<tr>
<td>Rabbit anti- HUS1</td>
<td>Cell Signaling Technology</td>
<td>Cat# 16416, RRID:AB_2798762</td>
</tr>
<tr>
<td>mouse Anti-a-actin</td>
<td>Sigma-Aldrich</td>
<td>Cat# A541, RRID:AB_476744</td>
</tr>
<tr>
<td>Goat anti-Mouse IgG-HRP</td>
<td>GenDepot</td>
<td>Cat# SA201</td>
</tr>
</tbody>
</table>

(Continued on next page)
### REAGENT or RESOURCE NAME

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE NAME</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>and goat anti-Rabbit IgG-HRP</td>
<td>GenDepot</td>
<td>Cat# SA202</td>
</tr>
<tr>
<td>PE Mouse Anti-Human CD11b</td>
<td>BD Biosciences</td>
<td>Cat# 561001, RRID:AB_10563205</td>
</tr>
<tr>
<td>FITC Mouse Anti-Human CD45</td>
<td>BD Biosciences</td>
<td>Cat# 347463, RRID:AB_40030</td>
</tr>
<tr>
<td>Alexa Fluor 647 Rat Anti-Mouse CD31</td>
<td>BD Biosciences</td>
<td>Cat# 563608, RRID:AB_2738313</td>
</tr>
</tbody>
</table>

### CHEMICALS, PEPTIDES, AND RECOMBINANT PROTEINS

<table>
<thead>
<tr>
<th>CHEMICALS</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSA Reagent, Biotin-XX Tyramide</td>
<td>Fisher Scientific</td>
<td>Cat# T20947</td>
</tr>
<tr>
<td>Dapi4,6-Diamidin-2-phenylindole (DAPI)</td>
<td>Sigma-Aldrich</td>
<td>Cat# D 9564</td>
</tr>
<tr>
<td>x-tremeGENE HP DNA transfection reagent</td>
<td>Sigma-Aldrich</td>
<td>Cat# 6366244001</td>
</tr>
<tr>
<td>Tamoxifen</td>
<td>Sigma-Aldrich</td>
<td>Cat# T5648</td>
</tr>
<tr>
<td>Tissue-Tec O.C.T</td>
<td>Sakura-Finetek</td>
<td>Cat# 4583</td>
</tr>
<tr>
<td>Fluorescence Mounting Medium</td>
<td>Dako</td>
<td>Cat# S3023</td>
</tr>
<tr>
<td>SYTOX Blue dead cell stain</td>
<td>ThermoFisher Scientific</td>
<td>Cat# S34857</td>
</tr>
<tr>
<td>DMEM</td>
<td>Milipore</td>
<td>Cat# FG0415</td>
</tr>
<tr>
<td>Dulbecco's MEM (10x)</td>
<td>Biochrom</td>
<td>Cat# F0455</td>
</tr>
<tr>
<td>FBS superior</td>
<td>Biochrom</td>
<td>Cat# F0615</td>
</tr>
<tr>
<td>DMEM F12</td>
<td>ThermoFisher Scientific</td>
<td>Cat# 11320-074</td>
</tr>
<tr>
<td>B27-supplements</td>
<td>ThermoFisher Scientific</td>
<td>Cat# 17504044</td>
</tr>
<tr>
<td>EGF</td>
<td>PeproTech</td>
<td>Cat# 100-15</td>
</tr>
<tr>
<td>FGF</td>
<td>PeproTech</td>
<td>Cat# 100-18B</td>
</tr>
<tr>
<td>TRIzol</td>
<td>ThermoFisher Scientific</td>
<td>Cat# 15596026</td>
</tr>
<tr>
<td>QuantiTect Reverse Transcription Kit</td>
<td>Qiagen</td>
<td>Cat# 205311</td>
</tr>
<tr>
<td>TaqMan™ Gene Expression Master Mix,</td>
<td>ThermoFisher Scientific</td>
<td>Cat# 4370074</td>
</tr>
<tr>
<td>Bazedoxifene acetate (BZA)</td>
<td>Sigma-Aldrich</td>
<td>Cat# PZ0018</td>
</tr>
<tr>
<td>Humarin</td>
<td>Biorbyt</td>
<td>Cat# orb372420</td>
</tr>
<tr>
<td>Humanin G (HNG)</td>
<td>Designer BioScience</td>
<td>Cat# H54838</td>
</tr>
<tr>
<td>SC144 hydrochloride</td>
<td>Sigma-Aldrich</td>
<td>Cat# SML0763</td>
</tr>
<tr>
<td>AZ20</td>
<td>Tocris Bioscience</td>
<td>Cat# 5198</td>
</tr>
<tr>
<td>Temozolomide</td>
<td>Sigma-Aldrich</td>
<td>Cat# T2577</td>
</tr>
<tr>
<td>Clodronate Liposomes</td>
<td>Liposoma BV</td>
<td>Cat# C-005</td>
</tr>
<tr>
<td>Corn Oil</td>
<td>Sigma-Aldrich</td>
<td>Cat# C8267</td>
</tr>
<tr>
<td>7-AAD</td>
<td>BD Pharmingen</td>
<td>Cat# 559925</td>
</tr>
<tr>
<td>Mirdametinib (PD0325901)</td>
<td>Selleckchem</td>
<td>Cat# F1036</td>
</tr>
<tr>
<td>Ravexortinib (RAV) GDC-0994</td>
<td>Selleckchem</td>
<td>Cat# F7554</td>
</tr>
<tr>
<td>Dextran (Biotin) Lysine Fixable (70kDA)</td>
<td>ThermoFisher Scientific</td>
<td>Cat# D1957</td>
</tr>
<tr>
<td>Oncostatin M (OSM) humn</td>
<td>Sigma-Aldrich</td>
<td>Cat# O9635-</td>
</tr>
<tr>
<td>Leukemia Inhibitory Factor (LIF) human</td>
<td>MedChemExpress</td>
<td>Cat# HY-P73276</td>
</tr>
<tr>
<td>Ciliary Neurotrophic Factor (CNTF) human</td>
<td>MedChemExpress</td>
<td>Cat# HY-P7145</td>
</tr>
<tr>
<td>Interleukin-6 (IL6) human</td>
<td>Sigma-Aldrich</td>
<td>Cat# H7416</td>
</tr>
<tr>
<td>Phalloidin-iFluor 488</td>
<td>Abcam</td>
<td>Cat# ab176753</td>
</tr>
</tbody>
</table>

### Critical commercial assays

<table>
<thead>
<tr>
<th>Assay Name</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>MaxFluor™ Mouse on Mouse Fluorescence Detection Kit (MaxFluor 488)</td>
<td>Dianova</td>
<td>Cat# MF01</td>
</tr>
<tr>
<td>Vectastain Elite ABC Kit (peroxidase standard) PK-6100</td>
<td>Vector Laboratories</td>
<td>Cat# PK-6100, RRID:AB_233681</td>
</tr>
<tr>
<td>CD109 TaqMan Gene Expression Assay</td>
<td>ThermoFisher Scientific</td>
<td>Cat# Hs00370347_m1</td>
</tr>
<tr>
<td>FPR1 TaqMan Geneexpression Assay</td>
<td>ThermoFisher Scientific</td>
<td>Cat# Hs00181830_m1</td>
</tr>
<tr>
<td>FPR2 TaqMan Geneexpression Assay</td>
<td>ThermoFisher Scientific</td>
<td>Cat# Hs00265954_m1</td>
</tr>
<tr>
<td>FPR3 TaqMan Geneexpression Assay</td>
<td>ThermoFisher Scientific</td>
<td>Cat# Hs01574392_m1</td>
</tr>
</tbody>
</table>

(Continued on next page)
### Reagent or Resource

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNTFR TaqMan Genexpression Assay</td>
<td>ThermoFisher Scientific</td>
<td>Cat#: Hs00181798_m1</td>
</tr>
<tr>
<td>IL6ST TaqMan Genexpression Assay</td>
<td>ThermoFisher Scientific</td>
<td>Cat#: Hs00174360_m1</td>
</tr>
<tr>
<td>ACTB TaqMan Genexpression Assay</td>
<td>ThermoFisher Scientific</td>
<td>Cat#: Hs99999903_m1</td>
</tr>
</tbody>
</table>

### Deposited data

| Raw and analyzed data of transcription profiling by array of TAM and total tumor cell samples | https://www.ebi.ac.uk/biostudies/arrayexpress/ | ArrayExpress: E-MTAB-13219 |
| Raw and analyzed data of transcription profiling by array of human GBM samples | https://www.ebi.ac.uk/biostudies/arrayexpress/ | ArrayExpress: E-MTAB-13220 |
| RNA-seq Raw and analyzed data of Humanin treatment on brain tumor cell lines | https://www.ebi.ac.uk/biostudies/arrayexpress/ | ArrayExpress: E-MTAB-13225 |
| Phosphoproteome raw data and analyzed data of Humanin treated brain tumor cells | https://www.ProteomeXchange.org | ProteomeXchange: PXD051404 |
| Copy number variation Raw data of primary brain tumor cells | https://www.ebi.ac.uk/biostudies/arrayexpress/ | ArrayExpress: E-MTAB-7649 |
| Effect of Humanin treatment on brain tumor vascular cells | https://www.ebi.ac.uk/biostudies/arrayexpress/ | ArrayExpress: E-MTAB-14064 |

### Experimental models: Cell lines

| HEK293T/17(ATCC) | Cellosaurus | RRID:CVCL_1926 |
| GL261 | National Cancer Institute, NCI-Frederick | RRID:CVCL_Y003 and Mastrella et al., 2019[^3] |
| U87MG | Cellosaurus | RRID:CVCL_0022 |
| NCH644 primary human GBM cells (called GBM-1 in this study) | Podergajš et al.[^5] | RRID:CVCL_X914 and Mastrella et al., 2019[^3] |
| NCH684 primary human GBM cells (called GBM-2 in this study) | Kalin et al.[^19] | Volmar et al., 2021[^18] |
| GBM20 primary human GBM cells (called GBM-3 in this study) | Kalin et al.[^19] | Volmar et al., 2021[^18] |
| G0128 primary human GBM cells (called GBM-4 in this study) | this study | N/A |
| G0147 primary human GBM cells (called GBM-5 in this study) | this study | N/A |
| Line#2 primary human GBM cells (called GBM-6 in this study) | Binda et al.[^55] | Volmar et al., 2021[^18] |
| Line#10 primary human GBM cells (called GBM-7 in this study) | Binda et al.[^55] and this study | N/A |
| Line#11 primary human GBM cells (called GBM-8 in this study) | Binda et al.[^55] and this study | N/A |
| pluripotent stem cells (hiPSC-MG) | N/A |

### Experimental models: Organisms/strains

| Gt(Rosa26)Sor-ACTB-2tdTomato-EGFP/Luo/J (here: Iox-STOP-Iox-tdTomato) | The Jackson Laboratory | RRID:JAX: 007676 and Kalin et al., 2021[^19] |
| C57BL6J | Charles River | Cat#: 632C57BL/6J |
| Hsd:Athymic Nude-Foxn1nu | Charles River | Cat#: 490CRATHHO |

### Recombinant DNA

| HN-WT-ORF plasmid (HN_WT-ORF_pcDNA3.1(+)-P2A-eGFP) | Genscript | N/A |
| HN-mutant-L9R plasmid (HN_L9R-mutant_pcDNA3.1(+)-P2A-eGFP) | Genscript | N/A |
| HN-mutant-C8A plasmid (HN_C8A-mutant_pcDNA3.1(+)-P2A-eGFP) | Genscript | N/A |

(Continued on next page)
**Lead contact**
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Rainer Glass (rainer.glass@med.uni-muenchen.de).
Materials availability
This study did not generate unique reagents.

Data and code availability
- Raw and analyzed data of RNA-seq and transcription profiling by array are publicly available under the accession numbers E-MTAB-13219, E-MTAB-13220, E-MTAB-13225 and E-MTAB-14064. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD051404.
- This paper does not report original code.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Mice
Animal experiments were carried out in compliance with the German law on animal welfare, and animal protocols were approved by local authorities “Regierung von Oberbayern” in Munich or the “Ministerium für Energiewende, Landwirtschaft, Umwelt, Natur und Digitalisierung des Landes Schleswig-Holstein (MELUND)” Kiel, Germany as required. Mice were housed in standardized cages in the animal centers of the Ludwig-Maximilians-University (LMU) Munich, the University of Kiel or the animal experiment center, received chow ad libitum and were kept under a circadian rhythm with 12 h light and dark cycles. ARRIVE guidelines were followed for all animal experiments. Mice used for experiments were of both sex and older than postnatal day 100. Tumor-take in all neuro-oncological models was R 98%; mice were only excluded from analysis when no tumor-growth observed. A comprehensive list of all transgenic mouse strains used for this study is given in the key resources table.

Human glioblastoma specimens
Glioblastoma samples were obtained from the Neurosurgery Department of the University Hospital, LMU Munich (Germany), from Charité university clinics (Berlin, Germany) and from the First Affiliated Hospital of Sun Yat-sen University (Guangzhou, China). This investigation received the endorsement of the Ethics Committees (under the project number 599-16) in Munich, in Berlin (under the license numbers EA112/2001, EA3/023/06 and EA2/101/08) and in Guangzhou (under the license number [2020]322).

Cell culture
Human, primary stem-like GBM cells hGBM-1 through 6 were cultured in DMEM-F12 medium supplemented with 1 x B27, 10 ng/mL human EGF, 10 ng/mL human fibroblast growth factor (FGF), and 1% penicillin-streptomycin. The mouse GBMs cell line GL261 was cultured under adherent condition in Dulbecco’s Modified Eagle Medium (DMEM) containing 10 ng/mL human EGF, 10 ng/mL human fibroblast growth factor (FGF), and 1% penicillin-streptomycin. All cells were maintained in a 37°C humidified incubator with 95% O2 and 5% CO2. The culture medium was changed once or twice weekly according to the growth rate. GL261 cells were split with trypsin when the cells occupied over 80% of the culture flask. Human GBMs cell lines were passaged with accutase when big spheres formed.

METHOD DETAILS

Transcriptomics
Human GBMs samples and controls (patients with lateral sclerosis) were collected and split into single cell. The samples were stained with CD11b and CD45 and sorted using flow cytometry. CD45+CD11b+ cells were collected from patients with GBMs and controls. Unlabeled cells (GBMs cells without CD45+CD11b+ cells) were also collected from patients with GBMs. 10,000 cells were collected from each sample and stored at −80°C. For microarray hybridization, mRNA was isolated from samples and converted into cDNA; the cDNA was labeled with biotin. Later, the labeled and fragmented single strand cDNA was spiked with cDNA hybridization controls, which served as an internal control for sensitivity and accuracy of the hybridization reaction as well as the wash and staining procedure. The spiked cDNA samples were hybridized at 45°C for 16.5 h on separate Affymetrix GeneChip HuGene ST 2.0 Arrays. After hybridization, microarrays were stained in two binding cycles using anti-biotin antibodies and a streptavidin-phycocerythrin conjugate. Subsequently, the microarrays were washed with increasing stringency and conserved in holding buffer using the Affymetrix GeneChip 3000 Fluidics Station in combination with the Affymetrix GeneChip Command Console (AGCC) - Fluidics Control Software v4.0.0. Fluorescent signal intensities were detected with the Affymetrix GeneChip 3000 Scanner and AGCC Scan Control Software v4.0.0 (Affymetrix). Automatic grid was arranged and raw data were processed to generate image and intensity files by the AGCC software. The software tools AGCC Viewer v4.0.0 and Expression Console v1.4.1.46 (both Affymetrix) were used for visualization of the performance of microarray analysis.

hGBM-1 through 6 were used for RNA sequencing. The same number of cells for each cell line was plated under both the control and HN 200 nM conditions. After 72 h, cells were counted and cell pellets were gained, resuspended in 100 μL Trizol, and stored at −80°C. Samples were sent to single cell discoveries for bulk RNA sequencing.
For the analysis, the obtained data were first filtered to remove genes with no or nearly no expression of the indicated gene dataset across all samples. The resulting dataset contained 16329 genes. The data were then normalized and transformed using regularized log transformation, which normalizes the data with respect to library size and transforms the count data to the log2 scale in a manner that minimizes the differences between samples for genes with small counts. The normalized dataset was later used to assess sample similarities and to calculate the fold changes between samples of interest. For the comparisons without sample replicates, the fold difference for each gene was calculated in a pairwise fashion. The regularized log-transformed data were used to calculate pairwise differences in the log scale. Single-sample Gene Set Enrichment Analysis (ssGSEA) was applied to analyze cell cycle related genes, which were extracted from the molecular signature database under ontology gene sets (MSigDB, http://www.broadinstitute.org/gsea/msigdb) using the ssGSEA method of the R software Gene Set Variation Analysis (GSVA) package.

**Proteomics**

For the analysis of the phosphoproteome, hGBM-1 cells were left untreated or were treated with 200 nM Humanin peptide for 15 min or 12 h. To obtain sufficient amount of proteins, cells were cultured under standard conditions (described above) to gain approx. 4 x 106 cells per condition (in triplicate). After treatment, cells were pelleted and directly frozen at –80 °C. Next, samples were independently processed using the phosphoproteomics EasyPhos procedure. In short, protein concentration was determined by BCA protein assay and samples were adjusted to equal concentrations. Sample preparation and mass spectrometry were exactly carried out as described by Humphrey et al.78. MaxQuant 2.4.14.0 was used to identify and quantify proteins and phosphopeptides with the following parameters: Database, Uniprot_UP000005640_Hsapiens_20231219; MS tol, 10ppm; MS/MS tol, 20ppm; Peptide FDR, 0.1; Protein FDR, 0.01 Min. peptide Length, 5; Variable modifications, Oxidation (M), Phosphorylation (ST); Fixed modifications, Carbamidomethyl (C); Peptides for protein quantitation, razor and unique; Min. peptides, 1; Min. ratio count, 2. For proteomic analysis, identified proteins were considered as statistically significant with FDR:0.05 and s0:1 (Two sample-test adjusted for multiple comparisons, Perseus). Phosphopeptide analysis was carried in Perseus. Mass spectrometry phosphoproteomics data have been deposited to the ProteomeExchange Consortium via the PRIDE partner repository (https://www.ebi.ac.uk/pride/archive) with the dataset identifier PXD051404.

**Q-RT-PCR**

Total RNA was extracted from cell pellets using TRIzol following Invitrogen’s TRIzol RNA isolation protocol. cDNA synthesis was performed using the QuantiTect Reverse Transcription Kit (Qiagen) according to the manufacturers protocol with 1 μg total RNA. Obtained cDNA was diluted to 5 ng/μL and used for following qPCR analysis. Gene expression was analyzed using real-time PCR TaqMan Gene expression assay (Thermo Fisher Scientific). Each TaqMan Gene Expression Assay (the table below) consists of sequence-specific PCR primers and TaqMan assay-FAM dye-labeled MGB probe. PCR amplifications were performed in 20 μL total volume reactions containing10 μL TaqMan Gene Expression Master Mix, 2 μL cDNA templates, 7 μL nuclease free water, and 1 μL TaqMan assay probe. PCR reactions were run on StepOnePlus Real-Time PCR System with 45 cycles under standard Mode. The expression level of target genes was normalized by ACTB.

**Genetic manipulation**

CD109 and Hus1 shRNA lentiviral constructs were obtained from BioCat, including three different shRNA target sequences each and one no target control. Lentiviral packaging plasmid psPAX2(#12260) and VSV-G envelope expressing plasmid pMD2.G(#12259) were obtained from Addgene. For lentiviral packaging HEK293T/17 (ATCC) cells were seeded in 6 well plates and cultured with 2 mL 10% FBS DMEM medium under the above conditions. When the cells have grown to 60% confluence, replace the fresh medium and prepare the transfection mix. shRNA, psPAX2 and pMD2.G plasmids were prepared by mixing them at a ratio of 4:3:2 (0.4 μg shRNA plasmid+0.3 μg psPAX2+0.2 μg pMD2.G), serum-free DMEM was then added to the mixed plasmid DNA to a total volume of 250 μL. X-tremeGENE HP DNA transfection reagent (Roche, Switzerland) in a ratio of 3:1 plasmid mixture volume was added to the mixture in the previous step (2.7 μl transfection reagent +0.1 μl plasmid mix). Incubate at room temperature for 15 min (after which blurring of the solution can be observed). Spread transfection complex dropwise on the HEK293T/17 cells. The supernatant containing lentiviral particles was collected after 2 days transfection. The supernatant was centrifuged at 2000 rpm for 5 min to remove cell debris and aliquoted for storage at –80 °C.

HN shRNA lentiviral is based on the shRNA sequence against Humanin hHN: CCGTGAGAGGGCCGGCATAAAGTTCTCTTTATGCCCGCCTCTTCAGGTTTTT77 was synthesized fused to the U6 promoter, cloned into the bicistronic pUC57 vector containing GFP and puromycin promoter and the lentivirous packaged (PackGene).

Lentiviral transduction: Human GBM cells were seeded into 6-well plates, the same amount of lentiviral particles were added, incubated overnight, and washed with PBS for 3 times. The expression of fluorescence gene was observed under fluorescence microscope, and proper concentration of antibiotics (puromycin) was selected according to killing curve test to obtain stable knock down cell lines.

Cells were prepared as a single cell suspension and seeded at a density of 500,000 cells/2mL per well in 6-well plates. Transfection was performed using LipofectamineTM reagent, according to the manufacturer’s protocol. The HN-WT plasmid (HN-WT-ORF_pCDNA3.1(+)-P2A-eGFP), HN-L9R plasmid (HN-L9R-mutant_pCDNA3.1(+)-P2A-eGFP) and HN-C8A plasmid (HN-C8A-mutant_pCDNA3.1(+)-P2A-eGFP) were transfected into hGBM cells. All three plasmids harbored the antibiotic (G418) resistance gene. To
select transfected cells, the antibiotic (G418) kill curve was tested for each cell line before transfection. Cells were selected and maintained in presence of G418.

**Cell-counting**

Wild type or genetically manipulated hGBMs were plated at a density of 100,000 cells (low density) or 1,000,000 cells (high density) in 2 mL growth factor-deprived medium (DMEM-F12 medium without EGF or FGF) in 6-well plates. Each group was prepared in triplicate. For the low-density group, the cells were counted 6 days after plating. For the high-density group, the cells were counted on day 2. Each experiment was independently repeated at least thrice. Previously, we confirmed that the GP130 inhibitor SC144 can block the protective effect of HN. For the experimental groups with SC144 treatment, the inhibitor was added on day 0.

To prepare conditioned medium hGBMs (expressing HN-WT, HN-C8A or HN-L9R) were seeded in plates at a concentration of 100,000 cells/ml in a growth factor-deprived medium. After 48 h, the cells were centrifuged at 400 G for 5 min, and the supernatant was collected. Wild type hGBMs (20,000) were plated in 500 µL conditioned medium in a 24-well plate. Three wells were prepared for each treatment group. The conditioned medium was changed every other day. The hGBM cell numbers were counted on day 7.

In additional experiments vehicle or SC144 (200 nM) was added to the conditioned medium. The effects of HN were modulated with BZA, AZ20 or Ravoxertinib (specific concentrations are outlined in the manuscript text): In experiments with BZA or Ravoxertinib hGBM cells were seeded at 100,000 cells per well in 2 mL medium on day 0, and vehicle bovine serum albumin (BSA)/HN (200 nM) and vehicle/BZA were added to the cells every other day. Cells were counted on day 7, and 100,000 cells were returned to the culture. Cells were counted again on day 14. The ATR inhibitor AZ20 was applied to 100,000 hGBM-1 cells in 2 mL medium (in 6-well plates on day 0) and treated with BSA/HN and vehicle/ATRI every other day. Cells were counted on day 6. The effect of AZ20 was also verified in HN-overexpressing cell line and HN-mutant cell lines.

**Immunodepletion**

HN-conditioned medium was obtained from hGBMs overexpressing the HN-WT peptide (medium was conditioned for 2 days). Immunodepletion (or generation of HN-containing controls) was performed using an HN antibody (or IgG isotype control) and protein A binding magnetic microbeads. First, the conditioned medium with HN antibody/IgG isotype control and 10% v/v protein A magnetic beads was incubated on ice for 30 min. The µ-columns were set on the MACS MultiStand and rinsed with 70% ethanol as elution buffer, followed by rinse with DMEM-F12 medium without growth factor. Then, the conditioned medium was removed from the ice and loaded onto µ-columns. HN was removed from the filtered medium as it should combine with the HN antibody that is connected to the protein A beads attached to the column rather than flow through. hGBM1 cells were then cultured at a density of 40,000 cells/ml in 150µL of HN-depleted or control medium in pre-coated 96-well plates for 5 days. Three replicates were prepared for each experiment after 5 days of culture. The effect of immunodepletion was evaluated by cell quantification and immunostaining.

**Cell cycle analysis**

hGBM-1 cells were cultured in growth factor-free medium under the following conditions: 1) BSA, 2) BSA+TMZ 100 µM, 3) HN 200 nM, and 4) HN 200 nM + TMZ 100 µM, with 500,000 cells in 2 mL medium for each condition. Compounds were added every other day and the cells were cultured for 5 days. On day 5, the cells were collected and split into single cells using Accutase, followed by three times washes with ice-cold PBS. The cells were then fixed with ice-cold 70% ethanol at 4 °C for 30 min. After fixation, the cells were centrifuged, and ethanol was discarded, followed by washing three times with PBS. Cells were filtered through a 40 µm strainer before resuspension in PBS. Then, 7-Amino-Actinomycin D (7-AAD) was added for staining of cell nuclei at the concentration of 5 µL (0.25 µg)/500 µL on cell suspension, and incubated for 10 min before analysis. Data acquisition was performed using BD Calibur at a low flow rate. FACS data analysis was performed using FCS Express software.

**Western blotting**

After electrophoresis, proteins in gel were transferred to nitrocellulose membrane in transfer buffer containing 15% methanol (Amer sham) by Trans-Blot Turbo Transfer System (Bio-Rad). The membrane was washed three times with TBST (0.05% Tween 20), followed by blocked with 10% skim milk/TBST. After washing three times with TBST, the membrane was incubated overnight with primary antibodies diluted in 5% BSA/TBST. The membrane was washed three times with TBST, followed by incubated for 1 h at RT with HRP conjugated secondary antibodies (GenDepot) diluted 1:3000 times in 5% BSA/TBST. After washing four times with TBST, enhanced chemi-luminescent detection (GenDEPOT) of proteins was performed. The following primary antibodies were purchased from Cell Signaling Technologies; AKT (9272), phospho-AKT S473 (4060), ATR (2790), phospho-ATR T1989 (30632), ERK1/2 (9102), phospho-ERK1/2 T202/Y204 (4370), GAPDH (5174), STAT3 (4904), phospho-STAT3 Y705 (9145), HUS1 (16416). Anti-a-actin antibody (A5441) was purchased from Millipore-Sigma. Secondary antibodies, Goat anti-Mouse IgG-HRP (SA201) and goat anti-Rabbit IgG-HRP (SA202) were purchased from GenDepot.

**Mouse brain slice culture**

Brains from 14-day-old C57BL6N mice were obtained and sectioned into 250 µm slices for culture using vibratome as described previously. The mouse-originated microglia were depleted using clodronated liposomes, a procedure which was obtained over 48 h. 5000 Human microglia-like cells from induced pluripotent stem cells (hiPS-microglia) and/or 5000 hGBM-1 cells were
inoculated into cultured, microglia-depleted mouse brain slices. Five groups were included in this experiment: 1) naive brain (no hIPS-microglia, no hGBM1), 2) hGBM1, 3) hIPS-microglia, 4) hGBM1 + hIPS-microglia, and 5) hGBM1 + hIPS-microglia + SC144. We analyzed brain slices from male and female mice in a 1:1 ratio. Mouse brain slices were cultured in medium (1 mL of DMEM with 10% heat inactivated FCS, 0.2 mM glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin for the initial culturing for 24 h, then changed to 50% DMEM with 25% of heat inactivated FCS, 25% of Hank’s balanced salt solution, 50 mM sodium bicarbonate, 2% glucose, 250 mg/mL insulin, 2.46 mg/mL glucose, 0.8 mg/mL vitamin C, 25 U/mL penicillin, 100 mg/mL streptomycin, and 5 mM Tris) for 5 days with a medium change every other day. Slices were then fixed with 4% PFA for 3 h. Samples were stored in 1 x Tris-buffered saline at 4°C until use. Immunofluorescence staining of cultured mouse brain samples was performed as follow. First, the samples were washed with PBST (PBS+0.1%Tween 20) thrice (5 min for each time), and transferred to primary antibody which was diluted in dilution buffer (5% Donkey serum +0.3% Triton-100 in PBS). Samples were incubated at 4°C for 24 h, and then were washed thrice with 30 min each time. The secondary antibody with the fluorophore was incubated at room temperature for 4 h, followed by washing (3 x 30 min). Finally, the samples were stained with DAPI for 30 min and washed with PBS for 10 min.

**In vivo experiments**

All animal experiments were conducted according to the protocols of the local authorities and the regulations of the National Guidelines for Animal Protection, Germany. All animals were kept in Walter Brendel Center with sufficient food and water ad libitum in standard cages in a cabinet with 12 h light and dark cycle. Mice were examined daily and sacrificed when they were symptomatic or at specific time-points, depending on the experimental plan. The mice were anesthetized intraperitoneally (i.p.) with a mixture of 2% Rompun (0.3 mL), 10% ketamine (1.02 mL) and 0.9% NaCl (4.86 mL) at a dosage of 7 μL/kg. The mice were then disinfected on the head with 7.5% povidone-iodine and eye-protected with Bepanthen cream, and a midline incision was made on the skin above the skull. After stabilization of the stereotactic frame in the flat-skull position, a puncture was carefully and gently made on the skull with a 21G needle at the coordinate of 1 mm anterior and 2 mm right to the bregma. The needle of a 22G Hamilton syringe was rinsed thoroughly with decreasing concentrations of ethanol (99%, 70%, and 50%), sterilized distilled water, and 1 x PBS before taking tumor cells. Tumor cells were prepared at a density of 100,000 cells/L in culture medium. 1 μL cell suspension was injected into each mouse 3 mm under the skull in 2 min. The needle was slowly withdrawn at 1 mm/min after injection. The inoculated mice were then sutured and returned to the cages.

**Intracerebral drug application**

One day before the operation, artificial cerebrospinal fluid (aCSF) was prepared as follows: 1) solution A was prepared by mixing 500 mL sterile water, 8.66 g NaCl, 0.244 g KCl, 0.206 g CaCl2 · 2H2O, and 0.163 g MgCl2 · 6H2O; 2) solution B was prepared by dissolving 0.214 g Na2HPO4 · 7H2O and 0.027 g NaH2PO4 · H2O in 500 mL sterile water; 3) solutions A and B was combined in a 1:1 ratio and the solution was filtered through a 0.22 μm filter. Mini-pumps (Alzet mini-osmotic pump model 2004, 0.25 μL per hour, lasts around 28 days) were filled with either 200 μL aCSF or 100 nM HN dissolved in aCSF. All prepared mini-pumps were pre-warmed by immersion in aCSF under 37°C for overnight. After hGBM-1 cell inoculation, mini-pumps were directly installed by gently pushing the pump under the skin of mice and stabilizing the needle into the puncture point.

BZA was dissolved in 10% v/v dimethyl sulfoxide (DMSO) and 90% v/v corn oil i.p. at 4 mg/kg or 40 mg/kg in mice. BZA was injected from day 7 after tumor inoculation and was injected five times a week until the end of the experiment. The control group was injected with the vehicle.

TMZ was dissolved in 5% v/v DMSO and 95% v/v saline at a concentration of 5 mg/mL, and was maintained on a shake until use. Mice were injected i.p. with 50 mg/kg from day 7 after tumor inoculation. The control group was injected with the vehicle. The exact injection schedules are introduced according to each experiment in the results section.

**Single cell preparation and fluorescence-activated cell sorting of intracerebrally HN-treated tumor vasculature**

Transgenic PDGFRB<sup>RFP</sup> reporter (Pdgfrb-creER, lox-STOP-lox-tdTomato)<sup>19</sup> mice were inoculated with mouse GBM cells (GL261, 1 x 10<sup>6</sup> cells/1 μL) and intracerebral infusion with Humanin (200 nM) via minipump or aCSF was performed. This experimental set-up was necessary to obtain pure cell fractions from GBM models. While endothelial cells can be purified from glioma by flow cytometry for CD31+ cells, separation of endothelia from pericytes in glioma is reliably achieved with PDGFRB<sup>RFP</sup> mice. The reason for this is that surface markers for pericytes (required for FACS) become ambiguous throughout gliomagenesis, e.g., since endothelia strongly express the pericyte marker PDGFRB<sup>05</sup> or since glioma cells express the pericyte marker NG2<sup>06</sup>. However, it is possible to specifically induce RFP expression in intratumoral pericytes by genetic recombination of PDGFRB<sup>RFP</sup> mice before the onset of tumorigenesis with Tamoxifen application (75 mg/kg body weight) injection one week before tumor inoculation). This labels pericytes in the tumor free brain (Angiogenesis. 2017 Nov; 20(4): 655–662) and the progeny of these recombined pericytes remains specifically labeled in the tumor bearing brain. At 14DPO mice were sacrificed, brains were harvested and the tumor mass was microdissected under a fluorescence-stereomicroscope (Leica). Single cells were obtained by triturating dissected GBM in PBS and subsequent treatment with 1 mg/mL collagenase-I followed by several wash-steps and filtering through a 40nm cell strainer.

FACS sorting was done using a MoFlo Astrios EQ (Beckman Coulter) equipped with 7 Lasers (355nm, 405nm, 488nm, 532nm, 561nm, 582nm, 642nm) and operated with a 70nm Nozzle at 88kHz on single cell sort mode. Cells were pregated using FSC/SSC debris.

Please cite this article in press as: Cheng et al., Myeloid cells coordinately induce glioma cell-intrinsic and cell-extrinsic pathways for chemoresistance via GP130 signaling, Cell Reports Medicine (2024), https://doi.org/10.1016/j.xcrm.2024.101658
brains were then removed from the skull and post-fixed in 4% PFA for 48 h, washed in 1x PBS and immersed in 30% sucrose in Dextran (biotin-labeled) at 1% in saline 15 min before sacrifice and transcardiac perfusion with 4% paraformaldehyde (PFA). The vascular permeability in brain tumors was determined by intravenous injection of 100 kDa Dextran leakage assay using ICELLNET. was performed by Enrichplot (1.18.3). To explore the cell-cell interaction in vascular cells, we performed cell communication analysis criteria). GSEA and GO analysis were performed with the R package ClusterProfiler (4.7.1), visualization of functional enrichment was performed by Enrichplot (1.18.3). To explore the cell-cell interaction in vascular cells, we performed cell communication analysis using ICELLNET.

Dextran leakage assay
Vascular permeability in brain tumors was determined by intravenous injection of 100 μL per mouse of a 70 kDa size lysine-fixable Dextran (biotin-labeled) at 1% in saline 15 min before sacrifice and transcardiac perfusion with 4% paraformaldehyde (PFA). The brains were then removed from the skull and post-fixed in 4% PFA for 48 h, washed in 1x PBS and immersed in 30% sucrose in 1x PBS solution until sunken to the bottom. From the frozen brains, 40 μm horizontal sections were made using a sliding microtome. After immunofluorescence staining against CD31 pictures were made on a TCS SP8 microscope (Leica). Per mouse four pictures at 40x magnification on three sections (12 in total) were made with the same laser settings. For the analysis of leakage of the dextran into the brain parenchyma the sections were photographed on 40 objective by tile-scan function with 16 fields on a TCS SP8 microscope (Leica). Dextran leakage into the brain parenchyma was obtained by subtracting the CD31 area from the dextran area (stained by AF647-streptavidin) using ImageJ.

Histology and immunostaining
Mice were anesthetized with Narcoren and perfused with PBS, followed by 4% PFA solution. Brains and other organs of interest were collected and immersed in 4% PFA at 4 °C for 24 h for post-fixation. The organs were then transferred to hypertonic sucrose solution (30% w/v in 1x PBS). The organs were embedded in Cryomatrix and frozen in the vapor phase of liquid nitrogen after achieving the same osmotic pressure as the sucrose solution. The brains were cut into 40 μm sections using a microtome and placed in cryoprotective liquid (with 25% glycerol, 25% ethylene glycol and 50% 1x PBS) for later use. The sectioned samples were stored in a 24-well plate and maintained at −20 °C in a freezer.

For immunocytochemistry, round glass (diameter: 12 mm) coverslips were placed in a 24-well plate (and covered with 500 μL poly-d-lysine 50 μg/mL) in each well for 1 h at room temperature. After coating, the coverslips were rinsed twice with sterilized water and left to air-dry for 1 h. hGBMs were split into single cell and plated at a density of 250,000 cells in 500 μL growth factor-deprived medium per well. Alternatively, 8-well ibidi plates were used coated with 300 μL poly-d-lysine and 20,000 cells per well were applied. The coverslips with adherent cells were gently rinsed with PBS and fixed with 4% PFA. The attached cells were then subjected to immunofluorescence staining.

The samples of interest were mounted on slides and promptly dried. H&E staining was performed in glass wares as follows: 1) the slides were immersed in 100% ethanol for 30 s for dehydration; 2) the sections were then transferred to Mayer’s hematoxylin solution for nuclei dye for 2 min; 3) the sections were rinsed with running distilled water for 5 min; 4) then, the sections were moved to 0.5% eosin solution for cytoplasm staining for 30 s; 4) briefly, the slides were rinsed in distilled water and transferred to increasing concentrations of ethanol for dehydration (1 min in 70%, 96% and 100% ethanol, respectively); 5) then the slides were transferred to Roti-Histol for 1 min; 6) Entellan was mounted on each slide before covering the coverslips; and 7) the stained sections were allowed to dry under the hood. Images for H&E staining were captured using Carl Zeiss Axioskop 2 microscope with Axiovision Rel. 4.9 software.

Immunofluorescence staining
The brain samples of interest were collected from cryoprotective liquid and placed in washing buffer PBST in a 12-well plate and washed for thrice with 5 min each time. This step was to rinse off the remaining cryoprotective reagent before staining. The samples were then transferred to blocking solution (5% normal Donkey serum in 0.3% Triton X-100) for 1 h at room temperature. After blocking, the brain sections were directly transferred to the primary antibody solution and incubated at 4 °C overnight. On the second day, the brain samples were rinsed thrice in washing buffer with 5 min each time before being transferred to a secondary antibody. Incubation was then performed at room temperature for 2 h, followed by a washing step, as described previously. The sections were then mounted on slides and air dried for 15 min. After the nuclei staining with DAPI, the slides were washed by rinsing in distilled water shortly. Finally, the slides were mounted with fluorescence mounting medium and covered with coverslips. As the cell samples were already on the coverslip, the mounting medium was dropped onto the slides, and the round coverslip with cells attached on it was covered on slides with the cell side facing the slide.

Immunofluorescence staining for human GBMs samples
Human paraffin-embedded samples were processed with the following steps for deparaffinization and antigen retrieval before staining: The tissue sections were immersed in Histol for 10 min at room temperature for deparaffinization. The samples were immersed in ethanol with decreasing gradients (100%, 96%, 70%, and 50%), each step for 30 s, fixed in 70% Aceton at −20 °C for 10 min, washed with PBST (thrice with 5 min). The samples were then cooked at 100 °C in Citrat Buffer (1.8 mM Citric acid and 8.2 mM
tri-Natriumcitrat-Dihydrat, adjusted to PH 6.0 with 2 mM NaOH) for 20 min, cooled for 20 min to room temperature, followed by washing thrice with PBST (5 min) each time and processed as described above.

**Immunohistochemistry for mouse samples**

Paraffin-embedded mouse xenograft samples were first subjected to deparaffinization and antigen retrieval. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 15 min at room temperature. The slides were then rinsed and blocked with 10% Donkey serum in PBS for 30 min the primary antibody was incubated for 1 h at room temperature, followed by 30 min incubation with a biotinylated secondary antibody. Finally, the sections were labeled with avidin-biotin-peroxidase for 30 min. The washing steps (thrice, 5 min each time) were applied between each antibody incubation. Signal visualization was achieved by incubation in 3,3′-diaminobenzidine (DAB) solution until the desired stain intensity developed. The samples were rinsed with tap water to prevent further signal development.

**Microscopy**

A Zeiss Axioskop-2 light microscope was used to perform imaging for H&E staining and immunohistochemistry. Evaluation of HUS1 fluorescence staining from immunodepletion experiments was performed using an Axio Observer A1 inverse fluorescence microscope. All other fluorescence staining was imaged using Leica confocal laser microscope SP8 confocal. A 20× objective with glycerol immersion was used for most quantifications. A 40× objective with glycerol immersion was used for higher magnification. All formats were set to 1024 x 1024 with a scan speed of 200–400 Hz. All channels were imaged separately to avoid crosstalk. Navigator was used when the overview was required. All images were adjusted according to the negative controls. Zoom-in was used in the region of interest. Tile scan was performed for the area that required more information from different layers of the sample to better visualize and capture the structure. Confocal images were later processed with LAS X (Leica) for further adjustment and export.

**Tumor volume quantification**

Mouse brains were cut horizontally for tumor volume quantification. Sections with tumor were collected every 0.4 mm in the dorsoventral axis (z axis), mounted, and stained with H&E. Later, the tumor area (A) in each section was measured using Axiovision Rel. 4.9 software. The tumor volume(V) was calculated as \( V = (Z_{\text{top}} - Z_{\text{bottom}}) \times (A_{\text{top}} + A_{\text{bottom}}) / n \), where \( Z \) is the section coordinate relative to the bregma in the atlas and \( n \) is the number of sections with tumors. HUS1 staining was performed on slides attached with cells. Three images were obtained with a 40× objective using confocal microscopy for each cell line. Subsequently, the images were imported into ImageJ software for intensity quantification. Images were first converted to an 8-bit format, then the stained area was selected in “Image-Adjust-Threshold”. The mean intensity value was obtained by selecting “Analyze-Measure”.

**Quantification of tumor vasculature and pericyte coverage**

Mouse sections stained with CD31 and PDGRB were photographed to quantify vessel length and density as well as pericyte coverage within the tumor area. For each mouse, three or four sections with good quality containing a tumor were prepared, and nine 40× magnification images per section were taken using a TCS SP8 microscope. Vessel length density was analyzed using AngioTool 0.6 software. Pericyte coverage was obtained by the ratio of PDGFRB+/CD31+ costained area of all CD31+ array by ImageJ.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those previously reported;18,20; experimental groups were not blinded. In all Figures, the data presented are representative of at least 3 independent experiments. Data-distribution was presented by mean - values and standard deviation of the mean; numbers of independent experiments or individual animals was indicated in the figures, legends or in the manuscript text. Student’s t, one-way/two-way ANOVA with Tukey post-hoc test or ANOVA with Bonferroni correction were used as indicated; in survival experiments, Kaplan–Meier curves were used and Log rank (Mantel-Cox) test was applied to determine statistical significance; primary endpoint was development of neurological symptoms clearly indicative of hGSC. \( p \) values are indicated as *\( p < 0.05 \), **\( p < 0.01 \), ***\( p < 0.001 \), and ****\( p < 0.0001 \) in all results. All statistical analyses were conducted using Graph Pad Prism 5.